Drugs & Aging

, Volume 24, Issue 9, pp 733–760 | Cite as

A Composite Screening Tool for Medication Reviews of Outpatients

General Issues with Specific Examples
  • Peter A. G. M. De Smet
  • Wilma Denneboom
  • Cees Kramers
  • Richard Grol
Review Article


Regular performance of medication reviews is prominent among methods that have been advocated to reduce the extent and seriousness of drug-related problems, such as adverse drug reactions, drug-disease interactions, drug-drug interactions, drug ineffectiveness and cost ineffectiveness. Several screening tools have been developed to guide practising healthcare professionals and researchers in reviewing the medication patterns of elderly patients; however, each of these tools has its own limitations. This review discusses a wide range of general prescription-, treatment- and patient-related issues that should be taken into account when reviewing medication patterns by implicit screening. These include generic and therapeutic substitution; potentially superfluous or inappropriate medications; potentially inappropriate dosages or duration of treatment; drug-disease and drug-drug interactions; under-treatment; making use of laboratory test results; patient adherence, experiences and habits; appropriate dosage forms and packaging. A broad selection of specific examples and references that can be used as a basis for explicit screening of medication patterns in outpatients is also offered.


Chronic Obstructive Pulmonary Disease Medication Review Betahistine Beers Criterion Home Medicine Review 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Peter A.G.M. De Smet works for the Scientific Institute Dutch Pharmacists, which is financially dependent on the Royal Dutch Society for the Advancement of Pharmacy (the professional pharmaceutical association in The Netherlands). The authors have no other sources of funding or conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Rollason V, Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging 2003; 20(11): 817–32PubMedCrossRefGoogle Scholar
  2. 2.
    De Smet PAGM, Dautzenberg M. Repeat prescribing: scale, problems and quality management in ambulatory care patients. Drugs 2004; 64: 1779–800PubMedCrossRefGoogle Scholar
  3. 3.
    Merle L, Laroche ML, Dantoine T, et al. Predicting and preventing adverse drug reactions in the very old. Drugs Aging 2005; 22(5): 375–92PubMedCrossRefGoogle Scholar
  4. 4.
    Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med 1996 Apr; 100(4): 428–37PubMedCrossRefGoogle Scholar
  5. 5.
    Stewart S, Pearson S, Luke CG, et al. Effects of home-based intervention on unplanned readmissions and out-of-hospital deaths. J Am Geriatr Soc 1998 Feb; 46(2): 174–80PubMedGoogle Scholar
  6. 6.
    Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000 Dec; 20(12): 1508–16PubMedCrossRefGoogle Scholar
  7. 7.
    Lowe CJ, Raynor DK, Purvis J, et al. Effects of a medicine review and education programme for older people in general practice. Br J Clin Pharmacol 2000 Aug; 50(2): 172–5PubMedCrossRefGoogle Scholar
  8. 8.
    Zermansky AG, Petty DR, Raynor DK, et al. Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice. BMJ 2001 Dec 8; 323(7325): 1340–3PubMedCrossRefGoogle Scholar
  9. 9.
    Sorensen L, Stokes JA, Purdie DM, et al. Medication reviews in the community: results of a randomized, controlled effectiveness trial. Br J Clin Pharmacol 2004 Dec; 58(6): 648–64PubMedCrossRefGoogle Scholar
  10. 10.
    Holland R, Lenaghan E, Harvey I, et al. Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ 2005 Feb 5; 330(7486): 293PubMedCrossRefGoogle Scholar
  11. 11.
    Medicare Australia. Home medicines review [online]. Available from URL: [Accessed 2005 Dec 28]
  12. 12.
    Bos E. Polyfarmacieproject bespaart kosten: achmea betaalt voor zorgactiviteiten polyfarmacieproject. Pharm Weekbl 2005; 140: 1052–3Google Scholar
  13. 13.
    Kring en VGZ sluiten contract: Zorgverzekeraar VGZ maakt Kring-apotheken voorkeursleverancier voor vijf jaar. Pharm Weekbl 2005; 140: 1510–1Google Scholar
  14. 14.
    Directions: the National Health Service Act 1977: the pharmaceutical services (advanced and enhanced services) (England) directions 2005. London: Department of Health, 2005Google Scholar
  15. 15.
    Shaw J, Seal R, Pilling M. Room for review: a guide to medication review: the agenda for patients, practitioners and managers. Task Force on Medicines Partnership and the National Collaborative Medicines Management Services Programme. London: Medicines Partnership, 2002Google Scholar
  16. 16.
    Denneboom W, Dautzenberg MG, Grol R, et al. Analysis of polypharmacy in older patients in primary care using a multidisciplinary expert panel. Br J Gen Pract 2006 Jul; 5(528): 504–10Google Scholar
  17. 17.
    Denneboom W, Dautzenberg MG, Grol R, et al. User-related pharmaceutical care problems and factors affecting them: the importance of clinical relevance. J Clin Pharm Ther 2005 Jun; 30(3): 215–23PubMedCrossRefGoogle Scholar
  18. 18.
    Shelton PS, Fritsch MA, Scott MA. Assessing medication appropriateness in the elderly: a review of available measures. Drugs Aging 2000 Jun; 16(6): 437–50PubMedCrossRefGoogle Scholar
  19. 19.
    Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents: UCLA Division of Geriatric Medicine. Arch Intern Med 1991 Sep; 151(9): 1825–32PubMedCrossRefGoogle Scholar
  20. 20.
    Aparasu RR, Mort JR. Inappropriate prescribing for the elderly: Beers criteria-based review. Ann Pharmacother 2000 Mar; 34(3): 338–46PubMedCrossRefGoogle Scholar
  21. 21.
    Viswanathan H, Bharmal M, Thomas III J. Prevalence and correlates of potentially inappropriate prescribing among ambulatory older patients in the year 2001: comparison of three explicit criteria. Clin Ther 2005 Jan; 27(1): 88–99PubMedCrossRefGoogle Scholar
  22. 22.
    Fialová D, Topinkova E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005 Mar 16; 293(11): 1348–58PubMedCrossRefGoogle Scholar
  23. 23.
    Van der Hooft CS, Jong GW, Dieleman JP, et al. Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria: a population-based cohort study. Br J Clin Pharmacol 2005 Aug; 60(2): 137–44PubMedCrossRefGoogle Scholar
  24. 24.
    Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA 2001 Dec 12; 286(22): 2823–9PubMedCrossRefGoogle Scholar
  25. 25.
    Pugh MJ, Fincke BG, Bierman AS, et al. Potentially inappropriate prescribing in elderly veterans: are we using the wrong drug, wrong dose, or wrong duration? J Am Geriatr Soc 2005 Aug; 53(8): 1282–9PubMedCrossRefGoogle Scholar
  26. 26.
    Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003 Dec 8; 163(22): 2716–24PubMedCrossRefGoogle Scholar
  27. 27.
    Kassam R, Martin LG, Farris KB. Reliability of a modified medication appropriateness index in community pharmacies. Ann Pharmacother 2003 Jan; 37(1): 40–6PubMedCrossRefGoogle Scholar
  28. 28.
    Hanlon JT, Artz MB, Pieper CF, et al. Inappropriate medication use among frail elderly inpatients. Ann Pharmacother 2004 Jan; 38(1): 9–14PubMedCrossRefGoogle Scholar
  29. 29.
    Bregnhøj L, Thirstrup S, Kristensen MB, et al. Reliability of a modified medication appropriateness index in primary care. Eur J Clin Pharmacol 2005 Nov; 61(10): 769–73PubMedCrossRefGoogle Scholar
  30. 30.
    Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol 1992 Oct; 45(10): 1045–51PubMedCrossRefGoogle Scholar
  31. 31.
    Fitzgerald LS, Hanlon JT, Shelton PS, et al. Reliability of a modified medication appropriateness index in ambulatory older persons. Ann Pharmacother 1997 May; 31(5): 543–8PubMedGoogle Scholar
  32. 32.
    Knight EL, Avorn J. Quality indicators for appropriate medication use in vulnerable elders. Ann Intern Med 2001 Oct 16; 135 (8 Pt 2): 703–10PubMedGoogle Scholar
  33. 33.
    Sellors J, Kaczorowski J, Sellors C, et al. A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ 2003 Jul 8; 169(1): 17–22PubMedGoogle Scholar
  34. 34.
    Wenger NS, Solomon DH, Roth CP, et al. The quality of medical care provided to vulnerable community-dwelling older patients. Ann Intern Med 2003 Nov 4; 139(9): 740–7PubMedGoogle Scholar
  35. 35.
    Higashi T, Shekelle PG, Solomon DH, et al. The quality of pharmacologic care for vulnerable older patients. Ann Intern Med 2004 May 4; 140(9): 714–20PubMedGoogle Scholar
  36. 36.
    Shekelle PG, MacLean CH, Morton SC, et al. Assessing care of vulnerable elders: methods for developing quality indicators. Ann Intern Med 2001 Oct 16; 135 (8 Pt 2): 647–52PubMedGoogle Scholar
  37. 37.
    MacLean CH. Quality indicators for the management of osteoarthritis in vulnerable elders. Ann Intern Med 2001 Oct 16; 135 (8 Pt 2): 711–21PubMedGoogle Scholar
  38. 38.
    McGavock H, Wilson-Davis K, Connolly JP. Repeat prescribing management: a cause for concern? Br J Gen Pract 1999 May; 49(442): 343–7PubMedGoogle Scholar
  39. 39.
    Robertson HA, MacKinnon NJ. Development of a list of consensus-approved clinical indicators of preventable drug-related morbidity in older adults. Clin Ther 2002 Oct; 24(10): 1595–613PubMedCrossRefGoogle Scholar
  40. 40.
    Oborne CA, Hooper R, Swift CG, et al. Explicit, evidence-based criteria to assess the quality of prescribing to elderly nursing home residents. Age Ageing 2003 Jan; 32(1): 102–8PubMedCrossRefGoogle Scholar
  41. 41.
    Woodward MC. Deprescribing: achieving better health outcomes for older people through reducing medications. J Pharm Pract Res 2003; 33: 323–8Google Scholar
  42. 42.
    Le Couteur DG, Hilmer SN, Glasgow N, et al. Prescribing in older people. Aust Fam Physician 2004 Oct; 33(10): 777–81PubMedGoogle Scholar
  43. 43.
    Farris KB, Ganther-Urmie JM, Fang G, et al. Population-based medication reviews: a descriptive analysis of the medication issues identified in a Medicare not-for-profit prescription discount program. Ann Pharmacother 2004 Nov; 38(11): 1823–9PubMedCrossRefGoogle Scholar
  44. 44.
    Bushardt RL, Jones KW. Nine key questions to address polypharmacy in the elderly. JAAPA 2005 May; 18(5): 32–7PubMedGoogle Scholar
  45. 45.
    Murphy JE. Generic substitution and optimal patient care. Arch Intern Med 1999 Mar 8; 159(5): 429–33PubMedCrossRefGoogle Scholar
  46. 46.
    Suh DC. Trends of generic substitution in community pharmacies. Pharm World Sci 1999 Dec; 21(6): 260–5PubMedCrossRefGoogle Scholar
  47. 47.
    De Smet PAGM. Leidraad geneesmiddelsubstitutie: Een medisch-farmaceutische leidraad. ’s-Gravenhage: Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie, 1990Google Scholar
  48. 48.
    Meyer MC. Generic drug product equivalence: current status. Am J Manag Care 1998 Aug; 4(8): 1183–9PubMedGoogle Scholar
  49. 49.
    Generic drugs. Med Lett Drugs Ther 2002 Oct 14; 44(1141): 89–90Google Scholar
  50. 50.
    Schall R, Muller FR, Muller FO, et al. Bioequivalence of controlled-release calcium antagonists. Clin Pharmacokinet 1997 Jan; 32(1): 75–89PubMedCrossRefGoogle Scholar
  51. 51.
    Bialer M, Yacobi A, Moros D, et al. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia 1998 May; 39(5): 513–9PubMedCrossRefGoogle Scholar
  52. 52.
    Besag FM. Is generic prescribing acceptable in epilepsy? Drug Saf 2000 Sep; 23(3): 173–82PubMedCrossRefGoogle Scholar
  53. 53.
    Oiling M, Mensinga TT, Barends DM, et al. Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharm Drug Dispos 1999 Jan; 20(1): 19–28CrossRefGoogle Scholar
  54. 54.
    Halkin H, Shapiro J, Kurnik D, et al. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching. Clin Pharmacol Ther 2003 Sep; 74(3): 215–21PubMedCrossRefGoogle Scholar
  55. 55.
    Hielema AP, De Smet PAGM. Diversiteit van bijsluiters als obstakel bij substitutie. Pharm Weekbl 1991; 126: 504–6Google Scholar
  56. 56.
    Tinke JL, De Smet PAGM. Data en feiten over generieke substitutie en therapeutische standaardisatie. Pharm Weekbl 1997; 132: 290–4Google Scholar
  57. 57.
    Hilleman DE, Wurdeman RL, Lenz TL. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease. Pharmacotherapy 2001 Apr; 21(4): 410–5PubMedCrossRefGoogle Scholar
  58. 58.
    McAlister FA, Laupacis A, Wells GA, et al. Users’ guides to the medical literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999 Oct 13; 282(14): 1371–7PubMedCrossRefGoogle Scholar
  59. 59.
    Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet 1999 Oct 2; 354(9185): 1202–4PubMedCrossRefGoogle Scholar
  60. 60.
    De Smet PAGM, Van der Kuy A, Bonsel GJ. Mogelijkheden en beperkingen van klassesubstitutie als doelmatigheidsinstrument in de geneesmiddelenvoorziening. Ned Tijdschr Geneeskd 2002 Mar 23; 146(12): 553–7PubMedGoogle Scholar
  61. 61.
    Soriano JB, Hoes AW, Meems L, et al. Increased survival with beta-blockers: importance of ancillary properties. Prog Cardiovasc Dis 1997 Mar; 39(5): 445–56PubMedCrossRefGoogle Scholar
  62. 62.
    Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999 Jun 26; 318(7200): 1730–7PubMedCrossRefGoogle Scholar
  63. 63.
    Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004 Nov 6; 364(9446): 1684–9PubMedCrossRefGoogle Scholar
  64. 64.
    Levy RA, Smith DL. Clinical differences among nonsteroidal antiinflammatory drugs: implications for therapeutic substitution in ambulatory patients. DICP 1989 Jan; 23(1): 76–85PubMedGoogle Scholar
  65. 65.
    Henry D, Lim LL, Garcia RL, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996 Jun 22; 312(7046): 1563–6PubMedCrossRefGoogle Scholar
  66. 66.
    Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998 Dec 5; 352(9143): 1830–1PubMedCrossRefGoogle Scholar
  67. 67.
    Krska J, Cromarty JA, Arris F, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing 2001 May; 30(3): 205–11PubMedCrossRefGoogle Scholar
  68. 68.
    Warholak-Juarez T, Rupp MT, Salazar TA, et al. Effect of patient information on the quality of pharmacists’ drug use review decisions. J Am Pharm Assoc (Wash) 2000 Jul; 40(4): 500–8Google Scholar
  69. 69.
    Olin J, Schneider L, Novit A, et al. Hydergine for dementia. Cochrane Database Syst Rev 2001 Jan; (2): CD000359Google Scholar
  70. 70.
    Flicker L, Grimley EG. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2001; (2): CD001011Google Scholar
  71. 71.
    James AL, Burton MJ. Betahistine for Meniere’s disease or syndrome. Cochrane Database Syst Rev 2001 Jan; (2): CD001873Google Scholar
  72. 72.
    De Backer TL, Van der Stichele RH, Warie HH, et al. Oral vasoactive medication in intermittent claudication: utile or futile? Eur J Clin Pharmacol 2000 Jun; 56(3): 199–206PubMedCrossRefGoogle Scholar
  73. 73.
    Moher D, Pham B, Ausejo M, et al. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. Drugs 2000 May; 59(5): 1057–70PubMedCrossRefGoogle Scholar
  74. 74.
    Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001 Feb; 48(2): 272–82PubMedCrossRefGoogle Scholar
  75. 75.
    Knutson D, Braun C. Diagnosis and management of acute bronchitis. Am Fam Physician 2002 May 15; 65(10): 2039–44PubMedGoogle Scholar
  76. 76.
    Polk B. Expectorants: help for acute cold bronchitis? Med Monatsschr Pharm 2002 Nov; 25(11): 379–81PubMedGoogle Scholar
  77. 77.
    Walters J, Walters E, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; (3): CD005374Google Scholar
  78. 78.
    De Smet PAGM. Drug therapy: herbal remedies. N Engl J Med 2002 Dec 19; 347(25): 2046–56PubMedCrossRefGoogle Scholar
  79. 79.
    Yeh GY, Eisenberg DM, Kaptchuk TJ, et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003 Apr; 26(4): 1277–94PubMedCrossRefGoogle Scholar
  80. 80.
    Homeopathy again: a questionable meta-analysis. Prescrire Int 1998 Jun; 7(35): 94–5Google Scholar
  81. 81.
    Shang A, Huwiler-Muntener K, Nartey L, et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet 2005 Aug 27; 366(9487): 726–32PubMedCrossRefGoogle Scholar
  82. 82.
    Gerety MB, Cornell JE, Plichta DT, et al. Adverse events related to drugs and drug withdrawal in nursing home residents. J Am Geriatr Soc 1993 Dec; 41(12): 1326–32PubMedGoogle Scholar
  83. 83.
    Graves T, Hanlon JT, Schmader KE, et al. Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med 1997 Oct 27; 157(19): 2205–10PubMedCrossRefGoogle Scholar
  84. 84.
    van Kraaij DJ, Jansen RW, Gribnau FW, et al. Loop diuretics in patients aged 75 years or older: general practitioners’ assessment of indications and possibilities for withdrawal. Eur J Clin Pharmacol 1998 Jun; 54(4): 323–7PubMedCrossRefGoogle Scholar
  85. 85.
    Hurenkamp GJB, Grundmeijer HGLM, Bindels PJE, et al. Chronisch gebruik van maagzuursecretieremmende medicatie in de huisartsenpraktijk in de regio Amsterdam. Ned Tijdschr Geneeskd 1999 Feb 20; 143(8): 410–3PubMedGoogle Scholar
  86. 86.
    Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001 Jun; 23(3): 116–7PubMedCrossRefGoogle Scholar
  87. 87.
    Hurenkamp GJB, Grundmeijer HGLM, Van der Ende A, et al. Afbouw van langdurig gebruik van maagzuurremmers is mogelijk. Huisarts Wet 2003; 46(7): 354–8CrossRefGoogle Scholar
  88. 88.
    Krol N, Wensing M, Haaijer-Ruskamp F, et al. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment Pharmacol Ther 2004 Apr 15; 19(8): 917–22PubMedCrossRefGoogle Scholar
  89. 89.
    Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006 Dec 27; 296(24): 2947–53PubMedCrossRefGoogle Scholar
  90. 90.
    Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. CMAJ 2003 Sep 16; 169(6): 557–64PubMedGoogle Scholar
  91. 91.
    Livingston G, Katona C. The place of memantine in the treatment of Alzheimer’s disease: a number needed to treat analysis. Int J Geriatr Psychiatry 2004 Oct; 19(10): 919–25PubMedCrossRefGoogle Scholar
  92. 92.
    Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer’s disease. London: National Institute for Clinical Excellence, 2001Google Scholar
  93. 93.
    Herbison P, Hay-Smith J, Ellis G, et al. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003 Apr 19; 326(7394): 841–4PubMedCrossRefGoogle Scholar
  94. 94.
    Froom J, Trilling J. Reducing antihypertensive medication use in nursing home patients. Arch Fam Med 2000 Apr; 9(4): 378–83PubMedCrossRefGoogle Scholar
  95. 95.
    Elliott WJ. Management of hypertension in the very elderly patient. Hypertension 2004 Dec; 44(6): 800–4PubMedCrossRefGoogle Scholar
  96. 96.
    Kapoor JR, Chaudry S, Agostini JV, et al. Systolic hypertension in older persons: how aggressive should treatment be? Prog Cardiovasc Dis 2006 May; 48(6): 397–406PubMedCrossRefGoogle Scholar
  97. 97.
    Bulpitt CJ, Beckett NS, Cooke J, et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003 Dec; 21(12): 2409–17PubMedCrossRefGoogle Scholar
  98. 98.
    Poole PJ, Black PN. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents. Am J Respir Med 2003; 2(5): 367–70PubMedCrossRefGoogle Scholar
  99. 99.
    Hamdy RC, Moore SW, Whalen K, et al. Reducing polypharmacy in extended care. South Med J 1995 May; 88(5): 534–8PubMedCrossRefGoogle Scholar
  100. 100.
    Williams BR, Nichol MB, Lowe B, et al. Medication use in residential care facilities for the elderly. Ann Pharmacother 1999 Feb; 33(2): 149–55PubMedCrossRefGoogle Scholar
  101. 101.
    Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999 Jun 17; 340(24): 1888–99PubMedCrossRefGoogle Scholar
  102. 102.
    Sweetman SC. Martindale: the complete drug reference. 34th ed. London: Pharmaceutical Press, 2005Google Scholar
  103. 103.
    Paulino El, Bouvy ML, Gastelurrutia MA, et al. Drug related problems identified by European community pharmacists in patients discharged from hospital. Pharm World Sci 2004 Dec; 26(6): 353–60PubMedGoogle Scholar
  104. 104.
    Stewart RB, Cooper JW. Polypharmacy in the aged: practical solutions. Drugs Aging 1994 Jun; 4(6): 449–61PubMedCrossRefGoogle Scholar
  105. 105.
    Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997 Oct 25; 315(7115): 1096–9PubMedCrossRefGoogle Scholar
  106. 106.
    Chow SL, Luzier AB, DiTusa L, et al. Acid-suppressive therapy use associated with antihypertensive agents. J Clin Pharmacol 2001 Jul; 41(7): 750–6PubMedCrossRefGoogle Scholar
  107. 107.
    Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006 Jan; 129 (1 Suppl.): 169–173SCrossRefGoogle Scholar
  108. 108.
    Kogut SJ, El Maouche D, Abughosh SM. Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. Pharmacotherapy 2005; 25(12): 1729–35PubMedCrossRefGoogle Scholar
  109. 109.
    Steele AC, Kohli N, Mallipeddi P, et al. Pharmacologic causes of female incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10(2): 106–10PubMedCrossRefGoogle Scholar
  110. 110.
    Schneider T, Rubben H, Michel MC. Die medikamenten-induzierte Dysfunktion der Harnblase. Urologe A 2003 Dec; 42(12): 1588–93PubMedCrossRefGoogle Scholar
  111. 111.
    Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 2002 May; 50(5): 836–42PubMedCrossRefGoogle Scholar
  112. 112.
    Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005 Apr 11; 165(7): 808–13PubMedCrossRefGoogle Scholar
  113. 113.
    Movig KL, Leufkens HG, Belitser SV, et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 2002 Jun; 11(4): 271–9PubMedCrossRefGoogle Scholar
  114. 114.
    Ness J, Hoth A, Barnett MJ, et al. Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. Am J Geriatr Pharmacother 2006 Mar; 4(1): 42–51PubMedCrossRefGoogle Scholar
  115. 115.
    Janssens HJ, van de Lisdonk EH, Janssen M, et al. Gout, not induced by diuretics? A case-control study from primary care. Ann Rheum Dis 2006 Aug; 65(8): 1080–3PubMedCrossRefGoogle Scholar
  116. 116.
    Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997 Jul 28; 157(14): 1531–6PubMedCrossRefGoogle Scholar
  117. 117.
    Kunin CM. Inappropriate medication use in older adults: does nitrofurantoin belong on the list for the reasons stated? [letter]. Arch Intern Med 2004 Aug 9; 164(15): 1701PubMedCrossRefGoogle Scholar
  118. 118.
    White WT, Harrison L, Dumas J. Nitrofurantoin unmasking peripheral neuropathy in a type 2 diabetic patient. Arch Intern Med 1984 Apr; 144(4): 821PubMedCrossRefGoogle Scholar
  119. 119.
    Volbeda F, Jonker AM, Vecht J, et al. Levercirrose door chronisch gebruik van nitrofurantoine. Ned Tijdschr Geneeskd 2004 Jan 31; 148(5): 235–8PubMedGoogle Scholar
  120. 120.
    Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. Drugs Aging 2003; 20(1): 23–57PubMedCrossRefGoogle Scholar
  121. 121.
    Graal MB, Wolffenbuttel BH. The use of sulphonylureas in the elderly. Drugs Aging 1999 Dec; 15(6): 471–81PubMedCrossRefGoogle Scholar
  122. 122.
    Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 1999 Jul; 16(7): 586–90PubMedCrossRefGoogle Scholar
  123. 123.
    Veitch PC, Clifton-Bligh RJ. Long-acting sulfonylureas: long-acting hypoglycaemia. Med J Aust 2004 Jan 19; 180(2): 84–5PubMedGoogle Scholar
  124. 124.
    Newnham DM. Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing. Drug Saf 2001; 24(14): 1065–80PubMedCrossRefGoogle Scholar
  125. 125.
    Yohannes AM, Hardy CC. Treatment of chronic obstructive pulmonary disease in older patients: a practical guide. Drugs Aging 2003; 20(3): 209–28PubMedCrossRefGoogle Scholar
  126. 126.
    Ohnishi A, Kato M, Kojima J, et al. Differential pharmacokinetics of theophylline in elderly patients. Drugs Aging 2003; 20(1): 71–84PubMedCrossRefGoogle Scholar
  127. 127.
    van Kan HJ, Jansen PH, Tuinte C, et al. Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps. Eur J Clin Pharmacol 2000 Jun; 56(3): 263–7PubMedCrossRefGoogle Scholar
  128. 128.
    Brinker AD, Beitz J. Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action. Am J Hematol 2002 Aug; 70(4): 313–7PubMedCrossRefGoogle Scholar
  129. 129.
    Managing patients with restless legs. Drug Ther Bull 2003 Nov; 41(11): 81–3Google Scholar
  130. 130.
    Van Marum RJ, Jansen PA. Toegenomen kans op een beroerte na gebruik van olanzapine of risperidon bij patienten met dementie. Ned Tijdschr Geneeskd 2005 Jan 22; 149(4): 165–7PubMedGoogle Scholar
  131. 131.
    Carnahan RM, Lund BC, Perry PJ, et al. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand 2006 Feb; 113(2): 135–41PubMedCrossRefGoogle Scholar
  132. 132.
    Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 2005 Sep 12; 165(16): 1882–8PubMedCrossRefGoogle Scholar
  133. 133.
    Shah RR. Drug development and use in the elderly: search for the right dose and dosing regimen (parts I and II). Br J Clin Pharmacol 2004 Nov; 58(5): 452–69PubMedCrossRefGoogle Scholar
  134. 134.
    Kinirons MT, O’Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol 2004 May; 57(5): 540–4PubMedCrossRefGoogle Scholar
  135. 135.
    Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004 Feb; 57(2): 121–6PubMedCrossRefGoogle Scholar
  136. 136.
    Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004 Jan; 57(1): 6–14PubMedCrossRefGoogle Scholar
  137. 137.
    Cohen JS. Avoiding adverse reactions: effective lower-dose drug therapies for older patients. Geriatrics 2000 Feb; 55(2): 54–60, 63PubMedGoogle Scholar
  138. 138.
    Lackner TE, Heard T, Glunz S, et al. Gastrointestinal disease control after histamine2-receptor antagonist dose modification for renal impairment in frail chronically ill elderly patients. J Am Geriatr Soc 2003 May; 51(5): 650–6PubMedCrossRefGoogle Scholar
  139. 139.
    Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000 Mar; 16(3): 165–77PubMedCrossRefGoogle Scholar
  140. 140.
    Gosselink AT, van Veldhuisen DJ, Crijns HJ. When, and when not, to use digoxin in the elderly. Drugs Aging 1997 Jun; 10(6): 411–20PubMedCrossRefGoogle Scholar
  141. 141.
    Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician 1998 Jan 1; 57(1): 107–16PubMedGoogle Scholar
  142. 142.
    Hoogendam A, Hofmeijer J, Frijns CJ, et al. Ernstig parkinsonisme ten gevolge van metoclopramide bij een patiente met polyfarmacie. Ned Tijdschr Geneeskd 2002 Jan 26; 146(4): 175–7PubMedGoogle Scholar
  143. 143.
    Touw DJ. Metabolisme van clomipramine. Pharm Weekbl 1992; 127: 1068–74Google Scholar
  144. 144.
    Dorhout-Doude van Troostwijk LJAE, Koopmans RP, Vermeulen HDB, et al. CYP1A2 en de klaring van clozapine: hulpmiddel ter bepaling van de dosis. Pharm Weekbl 2001; 136: 1439–42Google Scholar
  145. 145.
    Jansen PAF. Valkuilen bij medicatiegebruik door ouderen. Geneesmiddelenbulletin 2000; 34: 53–9Google Scholar
  146. 146.
    Jansen PAF. Werkgroep klinische gerontofarmacologie: geneesmiddelen interacties bij ouderen: welke zijn klinisch relevant? Ned Tijdschr Geneeskd 2003; 147: 595–9PubMedGoogle Scholar
  147. 147.
    Herings RM, Stricker BH, de Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med 1995 Sep 11; 155(16): 1801–7PubMedCrossRefGoogle Scholar
  148. 148.
    Wang PS, Bohn RL, Glynn RJ, et al. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001 Jun; 158(6): 892–8PubMedCrossRefGoogle Scholar
  149. 149.
    Rochon PA, Clark JP, Gurwitz JH. Challenges of prescribing low-dose drug therapy for older people. CMAJ 1999 Apr 6; 160(7): 1029–31PubMedGoogle Scholar
  150. 150.
    Gurwitz JH, Monette J, Rochon PA, et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997 May 12; 157(9): 978–84PubMedCrossRefGoogle Scholar
  151. 151.
    Rodenhuis N, De Smet PAGM, Barends DM. Patient experiences with the performance of tablet score lines needed for dosing. Pharm World Sci 2003 Aug; 25(4): 173–6PubMedCrossRefGoogle Scholar
  152. 152.
    Rodenhuis N, De Smet PAGM, Barends DM. The rationale of scored tablets as dosage form. Eur J Pharm Sci 2004; 21: 305–8PubMedCrossRefGoogle Scholar
  153. 153.
    Lapane KL, Hughes CM. Pharmacotherapy interventions undertaken by pharmacists in the Fleetwood phase III study: the role of process control. Ann Pharmacother 2006 Sep; 40(9): 1522–6PubMedCrossRefGoogle Scholar
  154. 154.
    Macfarlane J, Prewett J, Rose D, et al. Prospective case-control study of role of infection in patients who reconsult after initial antibiotic treatment for lower respiratory tract infection in primary care. BMJ 1997 Nov 8; 315(7117): 1206–10PubMedCrossRefGoogle Scholar
  155. 155.
    Schulman S. Clinical practice: care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003 Aug 14; 349(7): 675–83PubMedCrossRefGoogle Scholar
  156. 156.
    Batty GM, Oborne CA, Swift CG, et al. Development of an indicator to identify inappropriate use of benzodiazepines in elderly medical in-patients. Int J Geriatr Psychiatry 2000 Oct; 15(10): 892–6PubMedCrossRefGoogle Scholar
  157. 157.
    Woodward MC. Hypnotics: options to help your patients stop. Aust Fam Physician 2000; 29: 939–44PubMedGoogle Scholar
  158. 158.
    Oude Voshaar RC, Gorgels WJ, Mol AJ, et al. Behandelmethoden om langdurig benzodiazepinegebruik te staken. Ned Tijdschr Geneeskd 2001 Jul 14; 145(28): 1347–50PubMedGoogle Scholar
  159. 159.
    Haumschild MJ, Karfonta TL, Haumschild MS, et al. Clinical and economic outcomes of a fall-focused pharmaceutical intervention program. Am J Health Syst Pharm 2003 May 15; 60(10): 1029–32PubMedGoogle Scholar
  160. 160.
    Gorgels WJ, Oude Voshaar RC, Mol AJ, et al. Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: a prospective controlled intervention study. Drug Alcohol Depend 2005 Apr 4; 78(1): 49–56PubMedCrossRefGoogle Scholar
  161. 161.
    Hirschfeld RM. Antidepressants in long-term therapy: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 35–8PubMedCrossRefGoogle Scholar
  162. 162.
    Fremont P. Drug use in the elderly: use of psychotropic drugs in the elderly: overuse or underuse? Presse Med 1999 Oct 23; 28(32): 1794–9PubMedGoogle Scholar
  163. 163.
    McLeod PJ, Huang AR, Tamblyn RM, et al. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ 1997 Feb 1; 156(3): 385–91PubMedGoogle Scholar
  164. 164.
    Lindblad CI, Artz MB, Pieper CF, et al. Potential drug-disease interactions in frail, hospitalized elderly veterans. Ann Pharmacother 2005 Mar; 39(3): 412–7PubMedCrossRefGoogle Scholar
  165. 165.
    Zhan C, Correa-de-Araujo R, Bierman AS, et al. Suboptimal prescribing in elderly outpatients: potentially harmful drug-drug and drug-disease combinations. J Am Geriatr Soc 2005 Feb; 53(2): 262–7PubMedCrossRefGoogle Scholar
  166. 166.
    Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005 Aug 10; 294(6): 716–24PubMedCrossRefGoogle Scholar
  167. 167.
    Buurma H, De Smet PAGM, Kruijtbosch M, et al. Disease and intolerability documentation in electronic patient records. Ann Pharmacother 2005 Oct; 39(10): 1640–6PubMedCrossRefGoogle Scholar
  168. 168.
    Gray J, Majeed A, Kerry S, et al. Identifying patients with ischaemic heart disease in general practice: cross sectional study of paper and computerised medical records. BMJ 2000 Sep 2; 321(7260): 548–50PubMedCrossRefGoogle Scholar
  169. 169.
    Shakib S, George A. Monitoring: to infinity and beyond! Aust Fam Physician 2003 Dec; 32(12): 995–7PubMedGoogle Scholar
  170. 170.
    Questions and answers on COX-2 inhibitors. Press office European Medicines Agency, London, 27 June 2005, doc. ref. EMEA/210745/2005 corr [online]. Available from URL: [Accessed 2005 Aug 18]
  171. 171.
    Stockley IH. Drug interactions. 6th ed. London: Pharmaceutical Press, 2002Google Scholar
  172. 172.
    Hansten PD, Horn JR. The top 100 drug interactions: a guide to patient management. Edmonds (WA): H&H Publications, 2005Google Scholar
  173. 173.
    Tatro DS. Drug interaction facts 2005: the authority on drug interactions. St Louis (MA): Facts and Comparisons, 2005Google Scholar
  174. 174.
    Buurma H, De Smet PAGM, Egberts AC. Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions. Drug Saf 2006; 29(8): 723–32PubMedCrossRefGoogle Scholar
  175. 175.
    De Gier J. Commentaren Medicatiebewaking 2006/2007. Houten: Health Base, 2006Google Scholar
  176. 176.
    Malone DC, Abarca J, Hansten PD, et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc 2004 Mar; 44(2): 142–51CrossRefGoogle Scholar
  177. 177.
    Malone DC, Hutchins DS, Haupert H, et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 2005 Oct 1; 62(19): 1983–91PubMedCrossRefGoogle Scholar
  178. 178.
    Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003 Apr 2; 289(13): 1652–8PubMedCrossRefGoogle Scholar
  179. 179.
    Guedon-Moreau L, Ducrocq D, Duc MF, et al. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 2003 Nov; 59(8–9): 689–95PubMedCrossRefGoogle Scholar
  180. 180.
    Guedon-Moreau L, Ducrocq D, Duc MF, et al. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 2004 Feb; 59(12): 899–904PubMedCrossRefGoogle Scholar
  181. 181.
    Becker ML, Kallewaard M, Caspers PW, et al. Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Saf 2005; 28(5): 371–8PubMedCrossRefGoogle Scholar
  182. 182.
    Chen YF, Avery AJ, Neil KE, et al. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 2005; 28(1): 67–80PubMedCrossRefGoogle Scholar
  183. 183.
    Mathew TH. Drug-induced renal disease. Med J Aust 1992 May 18; 156(10): 724–8PubMedGoogle Scholar
  184. 184.
    Thomas MC. Diuretics, ACE inhibitors and NSAIDs: the triple whammy. Med J Aust 2000 Feb 21; 172(4): 184–5PubMedGoogle Scholar
  185. 185.
    Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002 Oct 17; 347(16): 1256–61PubMedCrossRefGoogle Scholar
  186. 186.
    Bouvy ML, Heerdink ER, Hoes AW, et al. Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors. Drug Saf 2003; 26(13): 983–9PubMedCrossRefGoogle Scholar
  187. 187.
    Loboz KK, Shenfield GM. Drug combinations and impaired renal function: the ‘triple whammy’. Br J Clin Pharmacol 2005 Feb; 59(2): 239–43PubMedCrossRefGoogle Scholar
  188. 188.
    Boyd IW, Mathew TH, Thomas MC. COX-2 inhibitors and renal failure: the triple whammy revisited [letter]. Med J Aust 2000 Sep; 173(5): 274PubMedGoogle Scholar
  189. 189.
    Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003 Jun; 325(6): 349–62PubMedCrossRefGoogle Scholar
  190. 190.
    Liu BA, Juurlink DN. Drugs and the QT interval: caveat doctor. N Engl J Med 2004 Sep 9; 351(11): 1053–6PubMedCrossRefGoogle Scholar
  191. 191.
    Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003 Jul; 23(7): 881–908PubMedCrossRefGoogle Scholar
  192. 192.
    Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000 Sep; 93(9): 457–62PubMedGoogle Scholar
  193. 193.
    Han L, McCusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001 Apr 23; 161(8): 1099–105PubMedCrossRefGoogle Scholar
  194. 194.
    Tune L, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992 Oct; 149(10): 1393–4PubMedGoogle Scholar
  195. 195.
    Wennmo K, Wennmo C. Drug-related dizziness. Acta Otolaryngol Suppl 1988; 455: 11–3PubMedCrossRefGoogle Scholar
  196. 196.
    Weiner DK, Hanlon JT, Studenski SA. Effects of central nervous system polypharmacy on falls liability in community-dwelling elderly. Gerontology 1998; 44(4): 217–21PubMedCrossRefGoogle Scholar
  197. 197.
    Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999 Jan; 47(1): 30–9PubMedGoogle Scholar
  198. 198.
    Ziere G, Dieleman JP, Hofman A, et al. Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol 2006 Feb; 61(2): 218–23PubMedCrossRefGoogle Scholar
  199. 199.
    Van der Velde N, Stricker BH, Pols HA, et al. Risk of falls after withdrawal of fall-risk-increasing drugs: a prospective cohort study. Br J Clin Pharmacol 2007 Feb; 63(2): 232–7PubMedCrossRefGoogle Scholar
  200. 200.
    Ensrud KE, Blackwell TL, Mangione CM, et al. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 2002 Oct; 50(10): 1629–37PubMedCrossRefGoogle Scholar
  201. 201.
    Landi F, Onder G, Cesari M, et al. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontol A Biol Sci Med Sci 2005 May; 60(5): 622–6PubMedCrossRefGoogle Scholar
  202. 202.
    Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med 2004 Jul 26; 164(14): 1567–72PubMedCrossRefGoogle Scholar
  203. 203.
    Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 1999 Jan; 47(1): 40–50PubMedGoogle Scholar
  204. 204.
    Espino DV, Jules-Bradley AC, Johnston CL, et al. Diagnostic approach to the confused elderly patient. Am Fam Physician 1998 Mar 15; 57(6): 1358–66PubMedGoogle Scholar
  205. 205.
    Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999 Jul; 15(1): 15–28PubMedCrossRefGoogle Scholar
  206. 206.
    van Dijk KN, de Vries CS, van den Berg PB, et al. Constipation as an adverse effect of drug use in nursing home patients: an overestimated risk. Br J Clin Pharmacol 1998 Sep; 46(3): 255–61PubMedCrossRefGoogle Scholar
  207. 207.
    Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001 Feb; 49(2): 200–9PubMedCrossRefGoogle Scholar
  208. 208.
    Steinman MA, Landefeld CS, Rosenthal GE, et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc 2006 Oct; 54(10): 1516–23PubMedCrossRefGoogle Scholar
  209. 209.
    Frankfort SV, Tulner LR, van Campen JP, et al. Evaluation of pharmacotherapy in geriatric patients after performing complete geriatric assessment at a diagnostic day clinic. Clin Drug Investig 2006; 26(3): 169–74PubMedCrossRefGoogle Scholar
  210. 210.
    Campbell SM, Roland MO, Shekelle PG, et al. Development of review criteria for assessing the quality of management of stable angina, adult asthma, and non-insulin dependent diabetes mellitus in general practice. Qual Health Care 1999 Mar; 8(1): 6–15PubMedCrossRefGoogle Scholar
  211. 211.
    Bouvy ML, Heerdink ER, Klungel OH, et al. Women with angina pectoris receive less antiplatelet treatment than men. Br J Gen Pract 1999 Apr; 49(441): 299–300PubMedGoogle Scholar
  212. 212.
    Romeijnders AC, Elders PJ. Summary of the guideline ‘Osteoporosis’ of the Dutch College of General Practitioners: Dutch College of General Practitioners. Ned Tijdschr Geneeskd 1999 Jul 31; 143(31): 1611–4PubMedGoogle Scholar
  213. 213.
    van Staa TP, Geusens P, Pols HA, et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005 Mar; 98(3): 191–8PubMedCrossRefGoogle Scholar
  214. 214.
    Bouvy ML, Buurma H, Egberts TC. Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention. J Clin Pharm Ther 2002 Apr; 27(2): 107–10PubMedCrossRefGoogle Scholar
  215. 215.
    van Dijk KN, ter Huurne K, de Vries CS, et al. Prescribing of gastroprotective drugs among elderly NSAID users in The Netherlands. Pharm World Sci 2002 Jun; 24(3): 100–3PubMedCrossRefGoogle Scholar
  216. 216.
    MacRae F, MacKenzie L, McColl K, et al. How to change NSAID prescribing. Pharm J 2004; 272: 249–52Google Scholar
  217. 217.
    Do you know the SCORE [online]? Available from URL: [Accessed 2005 Dec 27]
  218. 218.
    Landi F, Onder G, Cesari M, et al. Pain management in frail, community-living elderly patients. Arch Intern Med 2001 Dec 10; 161(22): 2721–4PubMedCrossRefGoogle Scholar
  219. 219.
    Auret K, Schug SA. Underutilisation of opioids in elderly patients with chronic pain: approaches to correcting the problem. Drugs Aging 2005; 22(8): 641–54PubMedCrossRefGoogle Scholar
  220. 220.
    Hendra TJ. Starting insulin therapy in elderly patients. J R Soc Med 2002 Sep; 95(9): 453–5PubMedCrossRefGoogle Scholar
  221. 221.
    Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 Nov 23; 360(9346): 1623–30PubMedCrossRefGoogle Scholar
  222. 222.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul 6; 360(9326): 7–22CrossRefGoogle Scholar
  223. 223.
    Ahmed A, Kiefe CI, Allman RM, et al. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 2002 Oct; 50(10): 1659–66PubMedCrossRefGoogle Scholar
  224. 224.
    Gage BF, Fihn SD, White RH. Warfarin therapy for an octogenarian who has atrial fibrillation. Ann Intern Med 2001 Mar 20; 134(6): 465–74PubMedGoogle Scholar
  225. 225.
    Ebell MH. Choosing between warfarin (coumadin) and aspirin therapy for patients with atrial fibrillation. Am Fam Physician 2005 Jun 15; 71(12): 2348–50PubMedGoogle Scholar
  226. 226.
    Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998 May 21; 338(21): 1516–20PubMedCrossRefGoogle Scholar
  227. 227.
    Schiff GD, Klass D, Peterson J, et al. Linking laboratory and pharmacy: opportunities for reducing errors and improving care. Arch Intern Med 2003 Apr 28; 163(8): 893–900PubMedCrossRefGoogle Scholar
  228. 228.
    Piergies AA, Worwag EM, Atkinson Jr AJ. A concurrent audit of high digoxin plasma levels. Clin Pharmacol Ther 1994 Mar; 55(3): 353–8PubMedCrossRefGoogle Scholar
  229. 229.
    Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003 Aug; 38(8): 843–53PubMedCrossRefGoogle Scholar
  230. 230.
    Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA 2001 Dec 12; 286(22): 2839–44PubMedCrossRefGoogle Scholar
  231. 231.
    Pillans PI, Landsberg PG, Fleming AM, et al. Evaluation of dosage adjustment in patients with renal impairment. Intern Med J 2003 Jan; 33(1–2): 10–3PubMedCrossRefGoogle Scholar
  232. 232.
    Corsonello A, Pedone C, Corica F, et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005 Apr 11; 165(7): 790–5PubMedCrossRefGoogle Scholar
  233. 233.
    Long CL, Raebel MA, Price DW, et al. Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother 2004 May; 38(5): 853–8PubMedCrossRefGoogle Scholar
  234. 234.
    Van Dijk EA, Drabbe NR, Kruijtbosch M, et al. Drug dosage adjustments according to renal function at hospital discharge. Ann Pharmacother 2006; 40: 1254–60PubMedCrossRefGoogle Scholar
  235. 235.
    Vidal L, Shavit M, Fraser A, et al. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 2005 Jul 30; 331(7511): 263PubMedCrossRefGoogle Scholar
  236. 236.
    Martin-Facklam M, Rengelshausen J, Tayrouz Y, et al. Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? Eur J Clin Pharmacol 2005 Jan; 60(11): 807–11PubMedCrossRefGoogle Scholar
  237. 237.
    Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet 1999 Nov; 37(5): 399–431PubMedCrossRefGoogle Scholar
  238. 238.
    Krahenbühl S. Anpassen der dosierung von medikamenten bei patienten mit nieren- oder lebeinsuffizienz. Schweiz Med Wochenschr 1998 Feb 7; 128(6): 189–94PubMedGoogle Scholar
  239. 239.
    Choudhury D, Ahmed Z. Drug-induced nephrotoxicity. Med Clin North Am 1997 May; 81(3): 705–17PubMedCrossRefGoogle Scholar
  240. 240.
    Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003 Jul 31; 349(5): 474–85PubMedCrossRefGoogle Scholar
  241. 241.
    Jenne JW. Effect of disease states on theophylline elimination. J Allergy Clin Immunol 1986 Oct; 78 (4 Pt 2): 727–35PubMedCrossRefGoogle Scholar
  242. 242.
    Pfeifer S. The effect of disease on the pharmacokinetics of drugs: 3. Cardiovascular, respiratory, neoplastic, thyroid diseases, diabetes, infections, mucoviscidosis, obesity, operations, burns etc. Pharmazie 1991 Dec; 46(12): 830–9PubMedGoogle Scholar
  243. 243.
    Shenfield GM. Influence of thyroid dysfunction on drug pharmacokinetics. Clin Pharmacokinet 1981 Jul; 6(4): 275–97PubMedCrossRefGoogle Scholar
  244. 244.
    O’Connor P, Feely J. Clinical pharmacokinetics and endocrine disorders: therapeutic implications. Clin Pharmacokinet 1987 Dec; 13(6): 345–64PubMedCrossRefGoogle Scholar
  245. 245.
    Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 2003 Nov; 10(6): 452–7PubMedCrossRefGoogle Scholar
  246. 246.
    Justo D, Prokhorov V, Heller K, et al. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand 2005 Mar; 111(3): 171–6PubMedCrossRefGoogle Scholar
  247. 247.
    Brass EP, Thompson WL. Drug-induced electrolyte abnormalities. Drugs 1982 Sep; 24(3): 207–28PubMedCrossRefGoogle Scholar
  248. 248.
    Nanji AA. Drug-induced electrolyte disorders. Drug Intell Clin Pharm 1983 Mar; 17(3): 175–85PubMedGoogle Scholar
  249. 249.
    Howes LG. Which drugs affect potassium? Drug Saf 1995 Apr; 12(4): 240–4PubMedCrossRefGoogle Scholar
  250. 250.
    Schwab M, Roder F, Morike K, et al. Drug-induced hyponatraemia in elderly patients. Br J Clin Pharmacol 1999 Jul; 48(1): 105–6PubMedGoogle Scholar
  251. 251.
    Madhusoodanan S, Bogunovic OJ, Moise D, et al. Hyponatraemia associated with psychotropic medications: a review of the literature and spontaneous reports. Adverse Drug React Toxicol Rev 2002; 21(1–2): 17–29PubMedGoogle Scholar
  252. 252.
    Ponce SP, Jennings AE, Madias NE, et al. Drug-induced hyperkalemia. Medicine (Baltimore) 1985 Nov; 64(6): 357–70Google Scholar
  253. 253.
    Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000 Sep; 109(4): 307–14PubMedCrossRefGoogle Scholar
  254. 254.
    Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004 Aug 5; 351(6): 543–51PubMedCrossRefGoogle Scholar
  255. 255.
    Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000 Nov 11; 356(9242): 1667–71PubMedCrossRefGoogle Scholar
  256. 256.
    Rogers JF, Nafziger AN, Bertino Jr JS. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002 Dec 15; 113(9): 746–50PubMedCrossRefGoogle Scholar
  257. 257.
    Van der Weide J, Steijns LS, van Weelden MJ, et al. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001 Jun; 11(4): 287–91PubMedCrossRefGoogle Scholar
  258. 258.
    Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001 Sep; 104(3): 173–92PubMedCrossRefGoogle Scholar
  259. 259.
    Balis FM, Adamson PC. Application of pharmacogenetics to optimization of mercaptopurine dosing. J Natl Cancer Inst 1999 Dec 1; 91(23): 1983–5PubMedCrossRefGoogle Scholar
  260. 260.
    Candelaria M, Taja-Chayeb L, Arce-Salinas C, et al. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives. Anticancer Drugs 2005 Oct; 16(9): 923–33PubMedCrossRefGoogle Scholar
  261. 261.
    Maitland ML, Vasisht K, Ratain MJ. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci 2006 Aug; 27(8): 432–7PubMedCrossRefGoogle Scholar
  262. 262.
    Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003 Feb 6; 348(6): 538–49PubMedCrossRefGoogle Scholar
  263. 263.
    Maitland-van der Zee AH, Klungel OH, Stricker BH, et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002 Aug; 163(2): 213–22PubMedCrossRefGoogle Scholar
  264. 264.
    Schelleman H, Stricker BH, de Boer A, et al. Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 2004; 64(16): 1801–16PubMedCrossRefGoogle Scholar
  265. 265.
    Maitland-van der Zee AH, Klungel OH, de Boer A. Pharmacogenetics in health-care practice. Pharm World Sci 2004 Oct; 26(5): 253–5PubMedCrossRefGoogle Scholar
  266. 266.
    Haga SB, Burke W. Using pharmacogenetics to improve drug safety and efficacy. JAMA 2004 Jun 16; 291(23): 2869–71PubMedCrossRefGoogle Scholar
  267. 267.
    Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994 Nov 26; 344(8935): 1453–7PubMedCrossRefGoogle Scholar
  268. 268.
    Serretti A, Cusin C, Rausch JL, et al. Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis. Psychiatry Res 2006 Nov 29; 145(1): 61–5PubMedCrossRefGoogle Scholar
  269. 269.
    Binder EB, Holsboer F. Pharmacogenomics and antidepressant drugs. Ann Med 2006; 38(2): 82–94PubMedCrossRefGoogle Scholar
  270. 270.
    Visser LE, Van Schaik RHN, Van Vliet M, et al. Allelic variants of cytochrome P450 2C9 modify the interaction between non-steroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther 2005; 77: 479–85PubMedCrossRefGoogle Scholar
  271. 271.
    Wang LS, Zhu B, El Aty AM, et al. The influence of St John’s wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 2004 Jun; 44(6): 577–81PubMedCrossRefGoogle Scholar
  272. 272.
    Burtonwood AM, Hinchliffe AL, Tinkler GS. A prescription for quality: a role for the clinical pharmacist in general practice. Pharm J 1998; 261: 678–80Google Scholar
  273. 273.
    Jameson JP, VanNoord GR. Pharmacotherapy consultation on polypharmacy patients in ambulatory care. Ann Pharmacother 2001 Jul; 35(7–8): 835–40PubMedCrossRefGoogle Scholar
  274. 274.
    Ellis SL, Billups SJ, Malone DC, et al. Types of interventions made by clinical pharmacists in the IMPROVE study: Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000 Apr; 20(4): 429–35PubMedCrossRefGoogle Scholar
  275. 275.
    Britten N, Jenkins L, Barber N, et al. Developing a measure for the appropriateness of prescribing in general practice. Qual Saf Health Care 2003 Aug; 12(4): 246–50PubMedCrossRefGoogle Scholar
  276. 276.
    Barber N, Bradley C, Barry C, et al. Measuring the appropriateness of prescribing in primary care: are current measures complete? J Clin Pharm Ther 2005 Dec; 30(6): 533–9PubMedCrossRefGoogle Scholar
  277. 277.
    Fried LP, Ferrucci L, Darer J, et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004 Mar; 59(3): 255–63PubMedCrossRefGoogle Scholar
  278. 278.
    Ferrucci L, Guralnik JM, Studenski S, et al. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. J Am Geriatr Soc 2004 Apr; 52(4): 625–34PubMedCrossRefGoogle Scholar
  279. 279.
    Shaw SM, Opit LJ. Need for supervision in the elderly receiving long-term prescribed medication. BMJ 1976 Feb 28; 1(6008): 505–7PubMedCrossRefGoogle Scholar
  280. 280.
    Focus on your medicines [online]. Available from URL: [Accessed 2007 Feb 14]
  281. 281.
    Bissell P, May CR, Noyce PR. From compliance to concordance: barriers to accomplishing a re-framed model of health care interactions. Soc Sci Med 2004 Feb; 58(4): 851–62PubMedCrossRefGoogle Scholar
  282. 282.
    Kerse N, Buetow S, Mainous III AG, et al. Physician-patient relationship and medication compliance: a primary care investigation. Ann Fam Med 2004 Sep; 2(5): 455–61PubMedCrossRefGoogle Scholar
  283. 283.
    Lau HS, Beuning KS, Postma-Lim E, et al. Non-compliance in elderly people: evaluation of risk factors by longitudinal data analysis. Pharm World Sci 1996 Apr; 18(2): 63–8PubMedCrossRefGoogle Scholar
  284. 284.
    McElnay JC, McCallion CR, al-Deagi F, et al. Self-reported medication non-compliance in the elderly. Eur J Clin Pharmacol 1997; 53(3–4): 171–8PubMedCrossRefGoogle Scholar
  285. 285.
    Barat I, Andreasen F, Damsgaard EM. Drug therapy in the elderly: what doctors believe and patients actually do. Br J Clin Pharmacol 2001 Jun; 51(6): 615–22PubMedCrossRefGoogle Scholar
  286. 286.
    Avorn J. Drug prescribing, drug taking, adverse reactions, and compliance in elderly patients. In: Salzman C, editor. Geriatric clinical psychopharmacology. 3rd ed. Baltimore (MD): Williams & Wilkins, 1998Google Scholar
  287. 287.
    Blais L, Bourbeau J, Sheehy O, et al. Inhaled corticosteroids in COPD: determinants of use and trends in patient persistence with treatment. Can Respir J 2004 Jan; 11(1): 27–32PubMedGoogle Scholar
  288. 288.
    Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005 Sep; 21(9): 1453–60PubMedCrossRefGoogle Scholar
  289. 289.
    Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005 Oct; 140(4): 598–606PubMedCrossRefGoogle Scholar
  290. 290.
    Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005 Jul; 11(7): 449–57PubMedGoogle Scholar
  291. 291.
    Van Wijk BL, Klungel OH, Heerdink ER, et al. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol 2006 Jan; 59(1): 11–7PubMedCrossRefGoogle Scholar
  292. 292.
    Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 1998 Jul; 20(4): 764–71PubMedCrossRefGoogle Scholar
  293. 293.
    Salas M, In’t Veld BA, van der Linden PD, et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin Pharmacol Ther 2001 Dec; 70(6): 561–6PubMedCrossRefGoogle Scholar
  294. 294.
    Kilbourne AM, Reynolds III CF, Good CB, et al. How does depression influence diabetes medication adherence in older patients? Am J Geriatr Psychiatry 2005 Mar; 13(3): 202–10PubMedGoogle Scholar
  295. 295.
    Home R. Patients’ beliefs about treatment: the hidden determinant of treatment outcome? J Psychosom Res 1999 Dec; 47(6): 491–5CrossRefGoogle Scholar
  296. 296.
    Home R, Clatworthy J, Polmear A, et al. Do hypertensive patients’ beliefs about their illness and treatment influence medication adherence and quality of life? J Hum Hypertens 2001 Aug; 15Suppl. 1: S65–8Google Scholar
  297. 297.
    Pound P, Britten N, Morgan M, et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med 2005 Jul; 61(1): 133–55PubMedCrossRefGoogle Scholar
  298. 298.
    Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997 Jan; 50(1): 105–16PubMedCrossRefGoogle Scholar
  299. 299.
    Paes AH, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm World Sci 1998 Apr; 20(2): 73–7PubMedCrossRefGoogle Scholar
  300. 300.
    Grymonpre RE, Didur CD, Montgomery PR, et al. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother 1998 Jul; 32(7–8): 749–54PubMedCrossRefGoogle Scholar
  301. 301.
    Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999 Sep; 37(9): 846–57PubMedCrossRefGoogle Scholar
  302. 302.
    Vrijens B, Belmans A, Matthys K, et al. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf 2006 Feb; 15(2): 115–21PubMedCrossRefGoogle Scholar
  303. 303.
    Wetzels GE, Nelemans PJ, Schouten JS, et al. Electronic monitoring of adherence as a tool to improve blood pressure control a randomized controlled trial. Am J Hypertens 2007 Feb; 20(2): 119–25PubMedCrossRefGoogle Scholar
  304. 304.
    Bova CA, Fennie KP, Knafl GJ, et al. Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav 2005 Mar; 9(1): 103–10PubMedCrossRefGoogle Scholar
  305. 305.
    MacLaughlin EJ, Raehl CL, Treadway AK, et al. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drags Aging 2005; 22(3): 231–55CrossRefGoogle Scholar
  306. 306.
    McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002 Dec 11; 288(22): 2868–79PubMedCrossRefGoogle Scholar
  307. 307.
    Van Eijken M, Tsang S, Wensing M, et al. Interventions to improve medication compliance in older patients living in the community: a systematic review of the literature. Drags Aging 2003; 20(3): 229–40CrossRefGoogle Scholar
  308. 308.
    Elliott RA, Barber N, Home R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann Pharmacother 2005 Mar; 39(3): 508–15PubMedCrossRefGoogle Scholar
  309. 309.
    Cramer JA. Enhancing patient compliance in the elderly: role of packaging aids and monitoring. Drags Aging 1998 Jan; 12(1): 7–15CrossRefGoogle Scholar
  310. 310.
    Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001 Aug; 23(8): 1296–310PubMedCrossRefGoogle Scholar
  311. 311.
    Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002 Mar; 24(3): 460–7PubMedCrossRefGoogle Scholar
  312. 312.
    Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drags 2002; 62(3): 443–62CrossRefGoogle Scholar
  313. 313.
    Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ 2004 Dec; 82(12): 935–9PubMedGoogle Scholar
  314. 314.
    Rivers PH. Compliance aids: do they work? Drugs Aging 1992 Mar; 2(2): 103–11PubMedCrossRefGoogle Scholar
  315. 315.
    Corlett AJ. Aids to compliance with medication. BMJ 1996 Oct 12; 313(7062): 926–9PubMedCrossRefGoogle Scholar
  316. 316.
    Nunney JM, Raynor DK. How are multi-compartment compliance aids used in primary care? Pharm J 2001; 267: 784–9Google Scholar
  317. 317.
    Raynor DK, Nunney JM. Medicine compliance aids are partial solution, not panacea [letter]. BMJ 2002 Jun 1; 324(7349): 1338PubMedCrossRefGoogle Scholar
  318. 318.
    Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006 Dec 6; 296(21): 2563–71PubMedCrossRefGoogle Scholar
  319. 319.
    Diette GB, Wu AW, Skinner EA, et al. Treatment patterns among adult patients with asthma: factors associated with overuse of inhaled beta-agonists and underuse of inhaled corticosteroids. Arch Intern Med 1999 Dec 13; 159(22): 2697–704PubMedCrossRefGoogle Scholar
  320. 320.
    Finfgeld-Connett DL. Treatment of substance misuse in older women: using a brief intervention model. J Gerontol Nurs 2004 Aug; 30(8): 30–7PubMedGoogle Scholar
  321. 321.
    MacFadyen L, Eadie D, McGowan T. Community pharmacists’ experience of over-the-counter medicine misuse in Scotland. J R Soc Health 2001 Sep; 121(3): 185–92CrossRefGoogle Scholar
  322. 322.
    Motola G, Mazzeo F, Rinaldi B, et al. Self-prescribed laxative use: a drug-utilization review. Adv Ther 2002 Sep; 19(5): 203–8PubMedCrossRefGoogle Scholar
  323. 323.
    Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drags 1998 Nov; 56(5): 811–24CrossRefGoogle Scholar
  324. 324.
    Hallas J, Lauritsen J, Villadsen HD, et al. Nonsteroidal antiinflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995 May; 30(5): 438–44PubMedCrossRefGoogle Scholar
  325. 325.
    Visser LE, Graatsma HH, Strieker BH. Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer disease. Br J Clin Pharmacol 2002 Feb; 53(2): 183–8PubMedCrossRefGoogle Scholar
  326. 326.
    van der Linden CM, Kerskes MC, Bijl AM, et al. Represcription after adverse drug reaction in the elderly: a descriptive study. Arch Intern Med 2006 Aug 14; 166(15): 1666–7PubMedCrossRefGoogle Scholar
  327. 327.
    Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 1999 Jun; 36(6): 425–38PubMedCrossRefGoogle Scholar
  328. 328.
    De Smet PAGM. Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004 Jul; 76(1): 1–17PubMedCrossRefGoogle Scholar
  329. 329.
    Mynors G, Ghalamkari H, Beaumont S, et al. Informed choice in medicine taking: drugs of porcine origin and their clinical alternatives: an introductory guide. London: Medicines Partnership, 2004Google Scholar
  330. 330.
    Aadil N, Houti IE, Moussamih S. Drug intake during Ramadan. BMJ 2004 Oct 2; 329(7469): 778–82PubMedCrossRefGoogle Scholar
  331. 331.
    Al Arouj M, Bouguerra R, Buse J, et al. Recommendations for management of diabetes during Ramadan. Diabetes Care 2005 Sep; 28(9): 2305–11PubMedCrossRefGoogle Scholar
  332. 332.
    Pickering G. Frail elderly, nutritional status and drugs. Arch Gerontol Geriatr 2004 Mar; 38(2): 174–80PubMedCrossRefGoogle Scholar
  333. 333.
    Golden AG, Petropoulos JB, Silverman MA, et al. The use of oral nutritional supplements and anorexigenic medications in homebound older adults. J Am Geriatr Soc 2003 May; 51(5): 724–6PubMedCrossRefGoogle Scholar
  334. 334.
    Lisberg RB, Higham C, Jayson MI. Problems for rheumatic patients in opening dispensed drug containers. Br J Rheumatol 1983 May; 22(2): 95–8PubMedCrossRefGoogle Scholar
  335. 335.
    Verheggen-Laming BN, Phiferons H, Mulder EF, et al. Comparison of packages for suppositories by patients with rheumatoid arthritis. Scand J Rheumatol 1988; 17(3): 161–5PubMedCrossRefGoogle Scholar
  336. 336.
    Diggory P, Fernandez C, Humphrey A, et al. Comparison of elderly people’s technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 2001 Mar 10; 322(7286): 577–9PubMedCrossRefGoogle Scholar
  337. 337.
    Ho SF, O’Mahony MS, Steward JA, et al. Inhaler technique in older people in the community. Age Ageing 2004 Mar; 33(2): 185–8PubMedCrossRefGoogle Scholar
  338. 338.
    Dow L, Fowler L, Lamb H. Elderly people’s technique in using dry powder inhalers: new inhaler devices are rarely used by older people in the community. BMJ 2001 Jul 7; 323(7303): 49–50PubMedCrossRefGoogle Scholar
  339. 339.
    Allen SC, Jain M, Ragab S, et al. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. Age Ageing 2003 May; 32(3): 299–302PubMedCrossRefGoogle Scholar
  340. 340.
    McDonald VM, Gibson PG. Inhalation-device polypharmacy in asthma. Med J Aust 2005 Mar 7; 182(5): 250–1PubMedGoogle Scholar
  341. 341.
    Winfield AJ, Jessiman D, Williams A, et al. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol 1990 Aug; 74(8): 477–80PubMedCrossRefGoogle Scholar
  342. 342.
    Burns E, Mulley GP. Practical problems with eye-drops among elderly ophthalmology outpatients. Age Ageing 1992 May; 21(3): 168–70PubMedCrossRefGoogle Scholar
  343. 343.
    Busche S, Gramer E. Verbesserung der augentropfenapplikation und compliance bei glaukompatienten: eine klinische studie. Klin Monatsbl Augenheilkd 1997 Oct; 211(4): 257–62PubMedCrossRefGoogle Scholar
  344. 344.
    Van Drooge MJ, De Smet PAGM. Hoe glaucoompatienten oogdruppels gebruiken: instructieprotocol onderzocht in proefproject. Pharm Weekbl 2000; 135: 1016–20Google Scholar
  345. 345.
    Blickle JF, Attali JR, Barrou Z, et al. Le diabète du sujet âgé. Diabetes Metab 1999 Mar; 25(1): 84–93PubMedGoogle Scholar
  346. 346.
    Jehle PM, Micheler C, Jehle DR, et al. Inadequate suspension of neutral protamine hagendorn (NPH) insulin in pens. Lancet 1999 Nov 6; 354(9190): 1604–7PubMedCrossRefGoogle Scholar
  347. 347.
    Brown A, Steel JM, Duncan C, et al. An assessment of the adequacy of suspension of insulin in pen injectors. Diabet Med 2004 Jun; 21(6): 604–8PubMedCrossRefGoogle Scholar
  348. 348.
    De Smet PAGM, Van de Vaart FJ. De ontwikkeling van het beroep. Pharm Weekbl 2006; 141: 1278Google Scholar
  349. 349.
    Simon SR, Gurwitz JH. Drug therapy in the elderly: improving quality and access. Clin Pharmacol Ther 2003 May; 73(5): 387–93PubMedCrossRefGoogle Scholar
  350. 350.
    Royal S, Smeaton L, Avery AJ, et al. Interventions in primary care to reduce medication related adverse events and hospital admissions: systematic review and meta-analysis. Qual Saf Health Care 2006 Feb; 15(1): 23–31PubMedCrossRefGoogle Scholar
  351. 351.
    Holland R, Smith R, Harvey I. Where now for pharmacist led medication review? J Epidemiol Community Health 2006 Feb; 60(2): 92–3PubMedCrossRefGoogle Scholar
  352. 352.
    Howard RL, Avery AJ. Pharmacist-led medication reviews can reduce patient morbidity? Age Ageing 2006 Nov; 35(6): 555–6PubMedCrossRefGoogle Scholar
  353. 353.
    Schmader KE, Hanlon JT, Pieper CF, et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med 2004 Mar 15; 116(6): 394–401PubMedCrossRefGoogle Scholar
  354. 354.
    Mannheimer B, Ulfvarson J, Eklof S, et al. Drug-related problems and pharmacotherapeutic advisory intervention at a medicine clinic. Eur J Clin Pharmacol 2006 Dec; 62(12): 1075–81PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Peter A. G. M. De Smet
    • 1
    • 2
  • Wilma Denneboom
    • 3
    • 4
  • Cees Kramers
    • 5
  • Richard Grol
    • 4
  1. 1.Scientific Institute Dutch PharmacistsThe HagueThe Netherlands
  2. 2.Department of Clinical Pharmacy, University Medical CentreRadboud University NijmegenNijmegenThe Netherlands
  3. 3.Apotheek MeindersmaDeventerThe Netherlands
  4. 4.Centre for Quality of Care Research, University Medical CentreRadboud University NijmegenNijmegenThe Netherlands
  5. 5.Department of Pharmacology and ToxicologyRadboud University NijmegenNijmegenThe Netherlands

Personalised recommendations